MacroGenics Reports 27% Response Rate in MGC026 Phase 1 Study
MacroGenics reported interim Phase 1 results showing a 27% response rate in heavily pretreated SCCHN patients and plans a front-line combination study with pembrolizumab.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.